LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (118)
2024
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
2023
-
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
Cancers, Vol. 15, Núm. 5
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
-
Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212
-
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185
-
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92
-
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721
-
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069
2022
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427
-
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308
-
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer
Cancer, Vol. 128, Núm. 9, pp. 1801-1811
2021
-
Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression: A network meta-analysis
Journal of Clinical Medicine, Vol. 10, Núm. 7
2019
-
Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without fgfr alterations
JCO Precision Oncology
-
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123
2018
-
30 Immunotherapy in advanced NSCLC-from the ' tsunami' of therapeutic knowledge to a clinical practice algorithm: Results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
ESMO Open, Vol. 3, Núm. 4
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
The Lancet Oncology, Vol. 19, Núm. 4, pp. 521-536
-
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 228-236
-
Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer
Oncotarget, Vol. 9, Núm. 28, pp. 19945-19960
-
Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer
Oncotarget, Vol. 9, Núm. 4, pp. 4395-4410